Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||
| Cash flow from continuing operating activities | -462.96%-393.65K | -865.50%-217.02K | -469.57%-630.72K | -300.96K | -276.2K | 108.46K | -22.48K | -110.74K |
| Net income from continuing operations | -634.92%-221.01K | -86.70%-182.73K | -700.70%-629.97K | ---1.23M | ---1.1M | --41.32K | ---97.88K | ---78.68K |
| Asset impairment expenditure | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Remuneration paid in stock | --20.13K | --0 | --372.06K | ---- | ---- | ---- | --0 | --0 |
| Other non cashItems | ---57.17K | ---38.83K | ---27.37K | --629.98K | ---- | ---- | ---- | ---- |
| Change In working capital | -347.00%-138.07K | -93.98%4.54K | -977.55%-345.44K | --303.16K | --203.92K | --55.9K | --75.4K | ---32.06K |
| -Change in receivables | -892.05%-139.89K | 84.25%-4.77K | -347.66%-29.29K | ---32.65K | ---31.86K | --17.66K | ---30.29K | --11.83K |
| -Change in prepaid assets | -198.78%-11.49K | -93.78%1.47K | 26.92%-12.39K | ---8.53K | ---11.29K | ---3.84K | --23.55K | ---16.95K |
| -Change in payables and accrued expense | -68.39%13.3K | -90.45%7.85K | -1,027.70%-303.77K | --344.35K | --247.07K | --42.08K | --82.14K | ---26.94K |
| Cash from discontinued investing activities | ||||||||
| Operating cash flow | -462.96%-393.65K | -865.50%-217.02K | -469.57%-630.72K | ---300.96K | ---276.2K | --108.46K | ---22.48K | ---110.74K |
| Investing cash flow | ||||||||
| Cash flow from continuing investing activities | 196.60%291.42K | 734.68%286.12K | -10,678.45%-2.4M | -540.56K | -571.44K | 98.25K | -45.08K | -22.29K |
| Net PPE purchase and sale | ---238.58K | -374.43%-213.88K | -360.84%-102.73K | ---542.52K | ---- | ---- | ---45.08K | ---22.29K |
| Net investment purchase and sale | 1,616.32%530K | --500K | ---2.3M | ---- | ---- | --30.88K | --0 | --0 |
| Net other investing changes | ---- | ---- | ---- | --1.96K | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||
| Investing cash flow | 196.60%291.42K | 734.68%286.12K | -10,678.45%-2.4M | ---540.56K | ---571.44K | --98.25K | ---45.08K | ---22.29K |
| Financing cash flow | ||||||||
| Cash flow from continuing financing activities | -1.6K | 3.7M | ||||||
| Net common stock issuance | ---- | ---- | ---- | --3.73M | ---- | ---- | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | ---34.88K | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||
| Financing cash flow | ---1.6K | ---- | ---- | --3.7M | ---- | ---- | ---- | ---- |
| Net cash flow | ||||||||
| Beginning cash position | -6.11%135.02K | -40.81%65.93K | 1,168.17%3.1M | --244.4K | --6.14K | --143.81K | --111.37K | --244.4K |
| Current changes in cash | -197.30%-103.83K | 113.00%69.1K | -2,180.32%-3.03M | --2.85M | --2.85M | --106.71K | --32.44K | ---133.03K |
| End cash Position | 408.36%31.19K | -6.11%135.02K | -40.81%65.93K | --3.1M | --3.1M | --6.14K | --143.81K | --111.37K |
| Free cash from | -459.57%-632.23K | -537.82%-430.9K | -451.35%-733.45K | ---843.48K | ---818.72K | --175.83K | ---67.56K | ---133.03K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.